Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization - Total (2017 - 2021)

Lexaria Bioscience's Depreciation & Amortization - Total history spans 5 years, with the latest figure at $27929.0 for Q2 2021.

  • For Q2 2021, Depreciation & Amortization - Total fell 0.54% year-over-year to $27929.0; the TTM value through Feb 2022 reached $27929.0, down 75.24%, while the annual FY2020 figure was $112750.0, 86.21% up from the prior year.
  • Depreciation & Amortization - Total for Q2 2021 was $27929.0 at Lexaria Bioscience, roughly flat from $27930.0 in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $28875.0 in Q3 2020 and bottomed at $375.0 in Q4 2017.
  • The 5-year median for Depreciation & Amortization - Total is $26195.0 (2019), against an average of $17293.0.
  • The largest annual shift saw Depreciation & Amortization - Total soared 4200.95% in 2019 before it decreased 1.24% in 2021.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $375.0 in 2017, then surged by 327.47% to $1603.0 in 2018, then surged by 1616.28% to $27512.0 in 2019, then increased by 1.52% to $27929.0 in 2020, then changed by 0.0% to $27929.0 in 2021.
  • Per Business Quant, the three most recent readings for LEXX's Depreciation & Amortization - Total are $27929.0 (Q2 2021), $27930.0 (Q1 2021), and $27929.0 (Q4 2020).